DWDenglong Wu

Denglong Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Denglong Wu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Urethral Reconstruction with RNA Interference and Polycaprolactone/Silk Fibroin/Collagen Electrospun Fiber in Rabbits

    by Chengdang Xu, Ying Liu, Chao Li, Weidong Zhou, Shengsong Huang, Wei Le, Zhe Hong, Denglong Wu

    Objective: The aim of the study was to evaluate the applications of TGF-β1 siRNA in cell-seeded scaffold to reconstruct urethra of rabbits. Methods: Autologous oral keratinocytes and TGF-β1 siRNA transfected fibroblasts were seeded onto polycaprolactone/silk fibroin/collagen (PSC) electrospun fiber to obtain a tissue-engineered mucosa. A ventral urethral mucosal defect was created in 16 male rabbits. Then the urethroplasty was performed with autogenic oral keratinocyte- and TGF-β1 siRNA transfected fibroblast-seeded PSC electrospun fiber in rabbits of experimental group (n = 8), or with no cells-seeded PSC electrospun fiber in rabbits of control group (n = 8). Retrograde urethrography and histological analyses were performed to evaluate the results of urethroplasty. Results: The oral keratinocytes and TGF-β1 siRNA transfected fibroblasts had good biocompatibility with PSC electrospun fiber. After urethroplasty, the urethra was kept in a wide caliber in experimental group, however, the strictures were observed in control group. Stratified epithelial layer and formation of capillary in the epithelial lower layer were observed after 6 months postsurgery in experimental group. Conclusion: Oral keratinocytes and TGF-β1 siRNA transfected fibroblasts can be used as a source of seed cells for urethral tissue engineering in rabbits. TGF-β-silenced fibroblasts are beneficial for the repair of urethral mucosa. PSC electrospun fiber is a good scaffold for tissue-engineering in urethral reconstruction.


  • Specific MAPK inhibitors prevent hyperglycemia-induced renal diseases in type 1 diabetic mouse model

    by Zhe Hong, Zongyuan Hong, Denglong Wu, Hezhongrong Nie

    Mitogen-activated protein kinase (MAPK) and renin–angiotensin system (RAS) play critical roles in the process of renal diseases, but their interaction has not been comprehensively discussed. In the present studies, we investigated the renoprotective effects of MPAK inhibitors on renal diseases in type 1 diabetic mouse model, and clarify the crosstalk among MAPK signaling. Type 1 diabetic mouse model was established in male C57BL/6 J mice, and treated with or without 10 mg/kg MAPK blockers, including ERK inhibitor PD98059, p38 inhibitor SB203850, and JNK inhibitor SP600125 for four weeks. Hyperglycemia induced renal injuries, but treating them with MAPK inhibitors significantly decreased glomerular volume and glycogen in renal tissues. Although slightly changed body weight and fasting blood glucose levels, MAPK inhibitors attenuated blood urea nitrogen, urea protein, and microalbuminuria. Administration also reduced the diabetes-induced RAS activation, including angiotensin II converting enzyme (c) and Ang II, which contributed to its renal protective effects in the diabetic mice. In addition, the anti-RAS of MAPK inhibitor treatment markedly reduced gene expression of tumor necrosis factor-α, interleukin-6, and inducible nitric oxide synthase, fibrotic accumulation, and transforming growth factor-β1 levels in renal tissues. Furthermore, chemical inhibitors and genetic siRNA results identified the crosstalk among the three MAPK signaling, and proved JNK signaling played a critical role in MAPK-mediated ACE pathway in hyperglycemia state. Collectively, these results support the therapeutic effects of MAPK-specific inhibitors, especially JNK inactivation, on hyperglycemia-induced renal damages.


  • A comparative study of diode laser and plasmakinetic in transurethral enucleation of the prostate for treating large volume benign prostatic hyperplasia: a randomized clinical trial with 12-month follow-up

    by Gang Wu, Zhe Hong, Chao Li, Cuidong Bian, Shengsong Huang, Denglong Wu

    The objective of this study is to compare the efficacy and safety of diode laser enucleation of the prostate (DiLEP) with plasmakinetic enucleation of the prostate (PKEP) for symptomatic benign prostatic hyperplasia (BPH) patients with large prostate (volume > 80 ml). From January 2013 to June 2014, 80 consecutive patients were randomized treated with DiLEP (n = 40) or PKEP (n = 40). Perioperative and postoperative outcome data were assessed during a 1-year follow-up. There were no significant preoperative differences between the two surgical groups. The mean prostate volumes in the DiLEP and PKEP groups were 98.6 and 93.3 ml, respectively. DiLEP was equivalent to PKEP in improvement in International Prostate Symptom Score (IPSS), quality of life scores, and maximum flow rate. Compared with PKEP, patients treated with DiLEP showed a lower risk of blood loss (P < 0.01), shorter bladder irrigation and catheterization times (P < 0.01), as well as shorter hospital stays (P < 0.01). Moreover, the DiLEP group was significantly superior to bipolar plasmakinetic group in the irritative symptoms. However, the operation time of the DiLEP group was longer than that of PKEP group (P = 0.02). Both DiLEP and PKEP are safe and effective methods for the treatment of BPH in large prostates (volume > 80 ml). Compared with PKEP, DiLEP provides a decreased risk of hemorrhage, reduced bladder irrigation, and catheterization times, as well as shorter hospital stays.


    • 1 July 2015
      • Vol. 21  (7) , 630-3

    [Meatoplasty with pedicle flap for meatal stenosis secondary to chronic balanitis].

    by Sheng-Song Huang, Ya-Ping Gui, Hua-Rong Luo, Min Wu, Qi-Min Zhang, Jun-Fiang Li, Deng-Long Wu

    To evaluate the effect of meatoplasty with the pedicle flap in the treatment of meatal stenosis secondary to chronic balanitis. We retrospectively analyzed 32 cases of meatal stenosis secondary to chronic balanitis treated by meato- plasty with the pedicle flap. All the patients had a history of chronic balanitis and had received meatal dilatation or simple ventral mea- totomy without significant effect. Their mean maximum urinary flow rate (Qmax) was (4.3 ± 2.4) ml/s. During the operation, A "/\"-shaped incision was made in the healthy epidermis and a flap was harvested from the frenulum. After complete removal of the scar, the flap was placed into the urethral wall, followed by reconstruction of the external urethral orifice. The patients were fol- lowed up for 6 to 30 months, which revealed smooth urination in all the patients with Qmax of (26.7 ± 4.5) ml/s and normal erectile function and uresiesthesis. With little invasiveness and few complications, meatoplasty with the pedicle flap is an ideal surgical method for the treatment of meatal stenosis secondary to chronic balanitis. However, there might be some change in the normal appearance of the balanus postoperatively, and its long-term effect needs further observation.

  • Variant allele of HSD3B1 increases progression to castration‐resistant prostate cancer

    by Gang Wu, Shengsong Huang, Kent L. Nastiuk, Jinliang Li, Jun Gu, Ming Wu, Qimin Zhang, Hanqing Lin, Denglong Wu

    BACKGROUND: 3β‐hydroxysteroid dehydrogenase type 1 (3βHSD1), which is a rate‐limiting enzyme that catalyzes the conversion of adrenal‐derived steroid dehydroepiandrosterone to dihydrotestosterone (DHT), may be a promising target for treating castration‐resistant prostate cancer (CRPC).METHODS: From 2004 to 2011, a total of 103 consecutive patients presenting with advanced prostate cancer were included in this study. All patients were treated with surgical castration as androgen‐deprivation therapy (ADT). Germline DNA was extracted from archived tissue from each patient and sequenced. PSA half‐time (representing rate to PSA nadir after ADT), the incidence of, and time to CRPC occurrence, and cause‐specific mortality rates were determined during the 3–10 years follow‐up. The perioperative data and postoperative outcomes are compared. The patients were retrospectively analyzed for survival time.RESULTS: Of the 103 patient samples analyzed, 18 harbored a heterozygous variant (1245C) HSD3B1 gene, while 85 patients were homozygous wild‐type (1245A) for HSD3B1. The two groups were homogenous for age, PSA, Gleason and metastases rate preoperatively. The incidence of CRPC observed in the variant group was significantly higher than that of wild‐type group (100% vs. 64.7%, respectively; P = 0.003). Despite this higher incidence of CRPC, there were no significant differences in time to develop CRPC, or in cause‐specific mortality. Further, neither PSA half‐time, nor time to biochemical recurrence were different between the variant and wild‐type groups.CONCLUSION: Prostate cancer patients who harbored the heterozygous variant HSD3B1 (1245C) are more likely to develop to CRPC, but do not have shorter time to biochemical recurrence, shorter survival time or higher mortality risk. Prostate 75:777–782, 2015.


    • 1 February 2015
      • Vol. 21  (2) , 170-4

    [Prostate cancer stem cells: advances in current research].

    by Gang Wu, Deng-Long Wu

    Prostate cancer is one of the most common malignancies threatening men's health, and the mechanisms underlying its initiation and progression are poorly understood. Last decade has witnessed encouraging progress in the studies of prostate cancer stem cells (PCSCs), which are considered to play important roles in tumor initiation, recurrence and metastasis, castration resistance, and drug resistance. Therefore, a deeper insight into PCSCs is of great significance for the successful management of prostate cancer. This article presents an overview on the location, origin, and markers of PCSCs as well as their potential correlation with tumor metastasis and castration resistance.

    • 1 November 2013
      • Vol. 19  (11) , 1007-10

    [Diagnosis and treatment of yolk sac tumor of the testis with hydrocele in children: report of 7 cases].

    by Sheng-Song Huang, Deng-Long Wu, Ya-Ping Gui, Xin Zhao, Hua Xie

    To study the clinical characteristics of yolk sac tumor of the testis with concomitant testicular hydrocele in children and the association between the two conditions in order to improve the diagnosis and treatment of the disease. We retrospectively analyzed the clinical data of 7 cases of stage-I yolk sac tumor of the testis with concomitant testicular hydrocele. The patients ranged in age from 6 to 14 (mean 11) months. As treatment, we performed radical high spermatic cord orchiectomy after diagnosis established on intraoperative frozen sections, and conducted follow-up visits by medical examination, serum alpha-fetoprotein (AFP) detection, chest X-ray, ultrasonography and CT for 3-41 (mean 17) months, every month in the first year, every 3 months in the second year and every 6 months in the third year after surgery. Postoperative pathology confirmed yolk sac tumor in all the cases, with negative incisal margin. The level of serum AFP were decreased to normal in 6 cases within 1 month after surgery, all diagnosed as at stage I, and cured without chemotherapy. The other 1 case, with the serum AFP level of 116 microg/L at 1 month after operation, was diagnosed as at stage II and received PVC chemotherapy, but lost to follow-up at 3 months post-operatively. Yolk sac tumor of the testis with concomitant testicular hydrocele is easily misdiagnosed in children. Ultrasonography is necessitated as routine examination in its diagnosis. Radical high spermatic cord orchiectomy can be performed for patients in stage I, and chemotherapy should follow for those in stage II. Its prognosis is similar to that of other yolk sac tumors. Hitherto, there has been no evidence for a definitive correlation between yolk sac tumor of the testis and hydrocele in children.


  • Tet1 is required for Rb phosphorylation during G1/S phase transition

    by Shengsong Huang, Ziqi Zhu, Yiqin Wang, Yanru Wang, Longxia Xu, Xuemei Chen, Qing Xu, Qimin Zhang, Xin Zhao, Yi Yu, et al.